The milestone is based on Genentech’s continued progress in preclinical development with an antibody-drug conjugate (ADC) utilizing Seattle Genetics’ technology. “We believe our ADC technology is contributing significantly
NCX 1020 is a nitric oxide (NO)-donating derivative of budesonide, a corticosteroid which is administered by inhalation for the long-term treatment of asthma, where it has been shown
Actelion and Merck formed an exclusive worldwide alliance in December 2003 to discover, develop and market new classes of renin inhibitors for patients suffering from cardio-renal diseases. Through
This randomized controlled study, known as the SMART trial, has enrolled 550 patients at 94 leading medical centers in the US, Canada, Europe and Australia. The trial is
In addition, the FDA has approved the enrollment in the study of patients with mastocytosis, an orphan disease involving new or abnormal cell growth, where Zyflo (zileuton tablets)
Under the agreement, VirtualScopics, a provider of imaging solutions utilizing biomarkers for pharmaceutical development, will provide analytical and other imaging services to Wyeth for use in the trial.
Public Citizen’s Health Research Group (HRG)’s petition was based on adverse reaction reports of life-threatening muscle damage (rhabdomyolysis) and kidney failure or impairment in patients taking Crestor. The
The trial was sponsored by the National Cancer Institute (NCI), under a cooperative R&D agreement between NCI and Genentech, and conducted by a network of researchers led by
The phase II clinical trial of GCAN 101 will commence at the medical center and include up to 30 patients suffering from metastatic melanoma, metastatic prostate or colon
Under the agreement, Repligen will receive funding for a phase I clinical trial to assess the oral bioavailability of the company’s proprietary formulation of uridine. This phase I
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.